Eli Lilly and Company (NYSE:LLY) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• Eli Lilly & Company has received a consensus rating of "Moderate Buy" from 23 analysts, with an average price target of $950.17.
• The company's recent quarterly earnings report showed a significant increase in revenue to $15.56 billion, surpassing analysts' expectations and reflecting a 37.6% year-over-year growth.
• Eli Lilly has announced a quarterly dividend of $1.50 per share, payable on September 10th, representing a 0.8% yield.

Shares of Eli Lilly and Company (NYSE:LLY - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the twenty-three analysts that are currently covering the firm, Marketbeat reports. Eight research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $950.1667.

Several equities research analysts have recently weighed in on the company. Erste Group Bank downgraded Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. Cantor Fitzgerald reduced their price target on Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating on the stock in a report on Wednesday, August 13th. Daiwa Capital Markets downgraded Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price target on the stock. in a report on Sunday, August 17th. UBS Group reduced their price target on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Finally, Guggenheim reduced their price objective on Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating on the stock in a report on Wednesday, August 13th.

Eli Lilly and Company Trading Down 2.2%

Shares of LLY stock opened at $726.35 on Monday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $942.35. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The stock's 50 day simple moving average is $743.84 and its two-hundred day simple moving average is $780.58. The company has a market cap of $687.46 billion, a PE ratio of 47.47, a price-to-earnings-growth ratio of 1.01 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the prior year, the business posted $3.92 earnings per share. The company's quarterly revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be issued a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.8%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's dividend payout ratio (DPR) is presently 39.22%.

Insider Activity at Eli Lilly and Company

In other news, Director Jamere Jackson acquired 200 shares of Eli Lilly and Company stock in a transaction on Friday, August 8th. The shares were bought at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the acquisition, the director directly owned 9,402 shares of the company's stock, valued at $6,013,143.12. This trade represents a 2.17% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Daniel Skovronsky acquired 1,000 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The shares were purchased at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the acquisition, the executive vice president directly owned 137,660 shares in the company, valued at $87,331,504. This trade represents a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 4,514 shares of company stock worth $2,894,841 over the last three months. Corporate insiders own 0.14% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of LLY. Duquesne Family Office LLC boosted its position in Eli Lilly and Company by 52.5% during the 1st quarter. Duquesne Family Office LLC now owns 94,830 shares of the company's stock valued at $78,321,000 after acquiring an additional 32,640 shares in the last quarter. Corient IA LLC bought a new stake in Eli Lilly and Company during the 1st quarter valued at $570,000. LS Investment Advisors LLC boosted its position in Eli Lilly and Company by 1.7% during the 1st quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock valued at $1,933,000 after acquiring an additional 40 shares in the last quarter. Cutter Capital Management LP bought a new stake in Eli Lilly and Company during the 1st quarter valued at $14,866,000. Finally, Prism Advisors Inc. bought a new stake in Eli Lilly and Company during the 1st quarter valued at $207,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.